Kernal Biologics Analysis: $11M Raised
What is Kernal Biologics?
Kernal Biologics develops an onco-selective mRNA therapeutics platform for engineering cells inside the body. The company says it delivers the right sequence to the right tissues and cells through precise targeting and selective translation. Its homepage and news items highlight scalable in vivo CAR T programming for cancer and autoimmune disease.
Location
700 Main St, Cambridge, Massachusetts, 02139, US
Employees
11-50
Founded
2016
Revenue
$0.6M
Business Model
Licensing proprietary mRNA technology and partnerships for drug development funding.
Investors
- Amgen
Product Features & Capabilities
- mRNA 2.0 platform, selectively delivered mRNA, precise targeting, therapeutic applications in oncology and immunology, onco-selective mRNA therapeutics, KR-335 immuno-oncology candidate, pipeline of mRNA therapies.
How much Kernal Biologics raised
Seed - $10.5 million
July 22, 2021Lead Investor: Hummingbird Ventures, Amgen
Who are the founders of Kernal Biologics
Market Focus
Kernal Biologics primarily focuses on the biotechnology industry, specifically developing mRNA-based therapies for oncology and immunology.
Competitors Overview
Kernal Biologics operates in the mRNA therapeutics market, focusing on oncology and immunology. Its main competitors include:
-
Strand Therapeutics: This company designs genetic circuits and small-molecule chemical inducers for precise control of therapeutic activities. They focus on self-amplifying RNA (saRNA) and have raised significant funding, which may allow for more tailored therapeutic responses.
-
Replicate Bioscience: They are developing self-amplifying RNA constructs aimed at cancer and autoimmune disorders. Their approach could lead to more effective treatments with lower dosages, enhancing patient safety and efficacy.
-
Orna Therapeutics: This company is pursuing circular RNA therapies, which offer prolonged expression dynamics and potentially more cost-effective manufacturing processes. Their innovations may provide longer-lasting therapeutic effects compared to traditional mRNA.
-
Laronde: Similar to Orna, Laronde is working on circular RNA constructs, claiming persistent protein expression for extended periods after administration, which could improve treatment outcomes.
Kernal Biologics differentiates itself by focusing on "stealth mRNA" that avoids recognition by the immune system and targets specific ribosome activity in cancerous tissues, aiming for high specificity in treatment.
See something that needs updating? Suggest edits to this profile.